PharmaMar’s Lurbinectedin to Be Marketed as Zepsyre After Approval as Ovarian Cancer Therapy .

JUNE 23, 2017

BY JOANA FERNANDES

Once approved, PharmaMar’s lurbinectedin (PM1183) will be marketed under the brand name Zepsyre as a treatment for solid tumors in ovarian, lung, and breast cancers.

Zepsyre is in its final stage of development as an anticancer treatment. Selecting a brand name is part of the approval process by the European Medicines Agency and the U.S. Food and Drug Administration before a drug reaches market.

“We trust in the potential of Zepsyre as a therapeutic alternative due to its novel mechanism of action and the antitumoral activity observed in all clinical trials for different type of tumors,” Luis Mora, managing director of PharmaMar’s Oncology Business Unit, said in a news release.

Zepsyre works by inhibiting RNA polymerase II, an enzyme essential for protein production, causing cancer cell death and halting tumor growth.

In a Phase 2 clinical trial for ovarian cancer patients who did not respond to platinum-based chemotherapy, treatment with Zepsyre induced an overall response rate of 22% and a disease control rate of 71%. Researchers also found that Zepsyre reverses IRF-1-dependent resistance to Platinol (cisplatin) in ovarian cancer tumors.

Zepsyre’s efficacy and safety also are being studied in two Phase 3 trials — one in platinum-resistant ovarian cancer (NCT02421588) and another in platinum-resistant small-cell lung cancers (ATLANTIS, NCT02566993). The endpoints in these studies are a change in progression-free-survival (PFS) induced by the treatment, overall survival, and overall response rate.

A Phase 2 trial with BRCA-mutated metastatic breast cancer patients (NCT01525589) showed that Zepsyre induced an overall response rate of 41%, meeting the study’s primary objective. PharmaMar plans to launch a pivotal Phase 3 study in patients with this disease as well.

Ovarian cancer develops when cells in the ovaries grow out of control, mainly affecting older women (half of the women diagnosed with ovarian cancer are 63 or older). It is more common among Caucasian women than African-American women.

According to estimates by the American Cancer Society, about 22,440 women in the U.S. will be diagnosed with ovarian cancer in 2017.

Yondelis . This is a New Option That Oncologists Should Consider For Frail Patients Who Have Soft Tissue Sarcoma .

Dr. Grignani on the Patient Population of Trabectedin for Sarcoma .

Giovanni Grignani, MD .

 Published Online: Friday, Jun 23, 2017 .

Yondelis . Informe Sobre las Prespectivas de Mercado del Periodo 2017 a 2022 ... Ocupa 150 Paginas y Tiene un Costo de 3000 $ !!! .

JUNE 23, 2017 BY ARUN PATIL .

Trabectedin Market Outlook 2022: Top Companies, Trends and Growth Factors Details for Business Development .





For Any Query or Customised Report, Contact Our Expert at:http://www.absolutereports.com/enquiry/pre-order-enquiry/10755504

... The Trabectedin Market to grow at a substantial Compound Annual Growth Rate during the forecast period 2017-2022. Trabectedin Market Report includes Regions Like: North America, Europe, Asia-Pacific (APAC), Middle East and Africa, Rest of World (ROW).

Report highlights include key market dynamics of sector. Various definitions and classification of the industry, applications of the industry and chain structure are given. The current market scenario and future prospects of the sector also have been studied. Additionally, prime strategical activities in the market, which includes product developments, mergers and acquisitions, partnerships, etc., are discussed.

The research report offers answers to several important questions related to the growth of the Trabectedin market. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

...

Get Full Report at $ 3000 (Single User License) at –http://www.absolutereports.com/purchase/10755504